Rhythm Biosciences Management
Management criteria checks 1/4
Rhythm Biosciences' CEO is David Atkins, appointed in May 2024, has a tenure of less than a year. total yearly compensation is A$409.24K, comprised of 12.1% salary and 87.9% bonuses, including company stock and options. directly owns 1.41% of the company’s shares, worth A$348.00K. The average tenure of the management team and the board of directors is 1.1 years and 1.1 years respectively.
Key information
David Atkins
Chief executive officer
AU$409.2k
Total compensation
| CEO salary percentage | 12.1% |
| CEO tenure | less than a year |
| CEO ownership | 1.4% |
| Management average tenure | 1.1yrs |
| Board average tenure | 1.1yrs |
Recent management updates
Recent updates
Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?
Dec 06
We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate
Aug 09We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely
Apr 11Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation
Dec 02We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely
Jul 19Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation
Mar 03Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?
Dec 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$409k | AU$49k | -AU$7m |
Compensation vs Market: David's total compensation ($USD254.39K) is about average for companies of similar size in the Australian market ($USD286.38K).
Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.
CEO
David Atkins (59 yo)
less than a year
Tenure
AU$409,243
Compensation
Dr. David Atkins, MBA, Ph. D., serves as Chief Executive Officer of Rhythm Biosciences Limited since May 13, 2024 and serves as its Managing Director and Director since September 30, 2024. He was Director...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | less than a year | AU$409.24k | 1.41% A$ 348.0k | |
| Financial Controller | 1.3yrs | AU$178.96k | no data | |
| General Counsel & Joint Company Secretary | 2.8yrs | no data | no data | |
| Joint Company Secretary | less than a year | no data | no data |
1.1yrs
Average Tenure
Experienced Management: RHY's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | less than a year | AU$409.24k | 1.41% A$ 348.0k | |
| Non-Executive Chairman | 5.2yrs | AU$369.11k | 12.83% A$ 3.2m | |
| Independent Non-Executive Director | 1.9yrs | AU$87.74k | no data | |
| Independent Non-Executive Director | no data | no data | no data |
1.1yrs
Average Tenure
60yo
Average Age
Experienced Board: RHY's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 09:09 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rhythm Biosciences Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stuart Roberts | Pitt Street Research Pty Ltd. |